Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

VetDC Announces New TANOVEA®-CA1 Publication and State of the Art Presentation at the Veterinary Cancer Society 2017 Annual Conference

VetDC,Inc.
Posted on: 03 Nov 17

VetDC, Inc., the leading veterinary cancer therapeutics company, today announced a new TANOVEA®-CA1 (rabacfosadine for injection) publication in Veterinary & Comparative Oncology. Data from this publication and several new VetDC-sponsored studies was prominently featured in a State of the Art presentation at the Veterinary Cancer Society (VCS) Annual Conference this past weekend in Portland, Oregon, with nearly 700 veterinary healthcare professionals in attendance.

“VetDC has generated an impressive body of data across multiple studies in over 500 patients which support the broad utility of TANOVEA-CA1 for treating canine lymphoma,” noted Dr. Brenda Phillips, a board-certified veterinary oncologist and clinical investigator at Ethos Veterinary Specialty Hospital in San Diego, CA. “Based on data from this recent publication, TANOVEA-CA1 will be considered as a first-line rescue agent for the treatment of lymphoma in dogs.”

The full Veterinary and Comparative Oncology publication can be accessed here.

TANOVEA-CA1 (rabacfosadine for injection) is a novel small molecule drug designed to preferentially target and attack rapidly dividing cancer cells implicated in lymphoma. TANOVEA-CA1 has demonstrated anti-tumor activity in both naïve and relapsed canine lymphoma cases, with a generally well-tolerated safety profile. TANOVEA-CA1 is administered intravenously every three weeks for up to five doses.

TANOVEA-CA1 is commercially available in the US for purchase by licensed veterinarians. TANOVEA-CA1 was recently granted conditional approval by the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM), making TANOVEA-CA1 the first and only new animal drug indicated for the treatment of lymphoma in dogs.

For additional prescribing, safety, and ordering information, please visit tanovea.com.

Important Safety Information: In dogs treated with TANOVEA-CA1, the most frequently reported adverse reactions included decreased white blood cell count, diarrhea, vomiting, decreased or loss of appetite, weight loss, decreased activity level, and skin problems. Please see the package insert for additional warnings, precautions, and contraindications.

About VetDC, Inc.

VetDC (www.vetdc.com), a Colorado State University startup company, is dedicated to bringing innovative pet cancer therapeutics to market. In addition to TANOVEA-CA1 for canine lymphoma, VetDC is developing VDC-597, a novel, dual-acting PI3K/mTOR inhibitor, for multiple veterinary cancers, such as hemangiosarcoma and osteosarcoma.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171103005522/en/

Business Wire
www.businesswire.com

Last updated on: 03/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.